Introduction
Prostate cancer (PCa) remains the most prevalent cancer in adult males, with the highest cancer incidence rates and as the third cause of cancer-related deaths in the developed world. 1 Androgen deprivation therapy (ADT) that profoundly reduces the levels of androgen hormones or blocks the action of androgen on tumor cell growth has been the gold standard treatment for metastatic prostate cancer since the 1940s. 2, 3 ADT can delay PCa progression for 2-3 years on average.
improve the efficacy of ADT may provide a major benefit to PCa patients. Notch signaling is a highly conserved signal pathway and plays a critical role from tissue homeostasis to carcinogenesis in mammals. 6, 7 There are four kinds of Notch receptors (named Notch1-4) and five available ligands (named Jag1/2, DLL1/3/4) located on the cell membrane. The interaction between a Notch receptor with its ligand on adjacent cell membrane leads to a sequential cleavage in Notch receptor by ADAM-family metalloproteases and g-secretase, respectively, to release a ligand-binding extracellular domain and a Notch intracellular domain (NICD). The NICD subsequently translocates into nucleus and works as a transcriptional coactivator binding to CSL (CBF1/Su(H)/Lag-1) complex for activation of the canonical Notch signaling. Aberrant Notch signaling has been widely demonstrated to be associated with tumor progression and therapeutic resistance in many types of cancers. 8, 9 ADT and docetaxel are the mainstay therapy for metastatic prostate cancer. 10 The latest clinical studies show that addition of docetaxel at the time of ADT initiation for metastatic PCa results in significantly longer overall and clinical progression-free survivals, and suggest that standard of care for metastatic PCa should be updated. 11, 12 Although Notch signaling has been demonstrated to play a critical role in the resistance to docetaxel in PCa 13 and targeting Notch signaling using a Notch signaling inhibitor (g-secretase inhibitor, GSI) is shown to be a very promising adjuvant agent to docetaxel, 14 the role of Notch signaling in response to ADT has not been determined. In our study, we found that Notch signaling is activated after androgen deprivation and contributes to the resistance to androgen deprivation in PCa cells. The anti-tumor efficacy of ADT can be significantly enhanced by inhibition of the Notch signaling together with ADT in vitro and in vivo. Our findings suggest a potential application of targeting Notch signaling as an adjuvant therapy to ADT in the treatment of PCa.
Materials and Methods

Cell culture and transfection
Human prostate cancer cell lines (LNCaP, C4-2, 22Rv1 and LAPC4) were purchased from American Type Culture Collection (ATCC). Cells were cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS, Gibco, Waltham, MA, USA) and maintained at 5% CO 2 at 378C. Notch3 siRNA or scrambled siRNA control (Thermo Scientific, Waltham, MA, USA) were transfected with Lipofectamine RNAiMax (Thermo Scientific), respectively.
Tissue samples
Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and national and international guidelines. Human tissues used in our study were reviewed and approved by the Committee for Ethical Review of Research Involving Human Subjects at Ren Ji Hospital. Twenty pairs of PCa patient specimens before and after ADT (Supporting Information  Table S1 ) were obtained from the Department of Urology, Ren ji Hospital (Shanghai, China), with signed informed consent from all patients. 
Chemical inhibitors
Plasmid construct
The fluorescent Notch signaling reporter system (pLVX-CSLP-AcGFP) was generated by replacing the CMV promoter in pLVX-acGFP1-N1 (Clontech, Mountain View, CA, USA) with the promoter containing multiple CSL binding sites which is obtained from 123CSL-d1EGFP plasmid (Addgene, Plasmid Number: #47684). 15 For construction of NICD1-4 induced lentiviral expression vectors, fragments of NICD1-4 were synthesized and cloned into pLVX-TetOnePuro Vector (Clontech), respectively.
Quantitative real-time PCR
Total RNA was extracted using Trizol reagent (Invitrogen, Waltham, MA, USA) and reverse transcribed for cDNA using Table S2 .
Western blotting
For western blot analysis, 1 3 10 7 cultured cells were lysed with RIPA buffer (Thermo Scientific, #89901) supplemented with phosphatase/proteinase inhibitors Cocktail (Cell Signaling Technology, #5872S). Nuclear protein was performed using Nuclear Protein Extraction Kit according to the manufacturer's protocols (Bio Teke, Beijing, China, Cat. No. PP2201). Specific primary antibodies were incubated at 48C overnight and then HRP-conjugated secondary antibody was probed at room temperature for 1 hr. Proteins were detected with HRP Substrate (Millipore, Bedford, MA, USA) and photographed using ECL (electro-chemiluminescence) detection instrument (Thermo Scientific). Cytoplasmic b-actin was used as an internal control for total protein analysis and nuclear proteins were normalized by TATA-binding protein (TBP). Detailed information of all antibodies used in our study was listed in Supporting Information Table S3 .
Immunohistochemistry and immunofluorescent staining
Immunohistochemistry (IHC) and immunofluorescent (IF) staining were performed as previously described. 16 Detailed information of all antibodies used in our study was listed in Supporting Information Table S3 .
Cell proliferation and apoptosis assays
For cell proliferation assays, 4,000 cells per well were seeded into 96-well plates and cultured for 2 days, 4 days or 6 days, respectively. At each time point, cell proliferation was analyzed with Cell Counting Kit 8 agent (CCK-8, Dojindo, Shanghai, China) according to the manufacturer's instructions.
For apoptosis assays, 1 3 10 6 cultured cells were trypsinized and washed with PBS. Then, they were stained with AnnexinV-APC (Biolegend, San Diego, CA, USA, Cat. No. #640920) and propidium iodide (PI, Sigma, St. Louis, MO, USA, Cat. No. P4170) in a dark place for 20 min. Samples were analyzed with flow cytometer (BD Accuri C6, BD Biosciences, San Jose, CA, USA) within 1 hr.
3D colony formation assays
Cells (2,000) were suspended into 100 ll RPMI-1640 medium and mixed with matrigel in equal volume (BD Biosciences, San Jose, CA, USA) on ice. The mixture was seeded into 48-well plate and incubated 20 min at 378C for concretion and was then covered by 800 ll culture medium for incubation. Relevant small-molecular inhibitors or vehicle were added in the medium on Day 0 and were kept for 10 days. Medium was refreshed every 2 days. After incubation for 10 days, colonies size and numbers were measured in 6 randomly selected visual fields by using microscopy under a 3200 magnification.
Subcutaneous xenografts experiments in nude mice
For subcutaneous xenografts experiment, 2.5 3 10 6 cells were suspended in serum-free RPMI-1640 medium and mixed with matrigel (BD Biosciences) at a 1:1 ratio. The mixture was injected s.c. into 5-week-old male BALB/C nude mice (SLAC, Shanghai, China). The tumor volume was measured every 3 days after implantation and calculated using the following equation: volume 5 0.5 3 tumor length 3 tumor width. 2 Mice were sacrificed 15 days after inoculation. Tumor masses were collected for weighting and IHC staining. All mice were kept in the SPF grade animal facility of Ren ji Hospital with a pathogen-free environment. All the animal protocols were reviewed and approved by the Ren ji Hospital Medical Experimental Animal Care Commission.
Statistical analysis
Prism GraphPad software was employed for all graphics and statistical analyses. Difference between two groups was analyzed by independent Student's t-test and analysis of variance (ANOVA). Immuno-staining intensity of Notch receptors in paired human PCa tissues was compared by paired Student's t-test. Results were considered statistically significant at p < 0.05.
Results
Higher expression of Notch receptors is associated with CRPC progression
To investigate a possible correlation between activation of the Notch signaling and progression of CRPC, we first analyzed the mRNA expression levels of various Notch receptors, ligands and Notch target genes in the dataset of Taylor et al. from the Oncomine database, which contains recurrent PCa samples after ADT. 17 We found that expression level of Notch3 (p < 0.001), Notch4 (p < 0.01), DLL4 (p < 0.001) and Hey1 (p < 0.01) was significantly upregulated in clinical recurrence samples after hormone therapy compared to those in samples without recurrence, and expression of Notch3 was negatively correlated with the overall survival (Figs. 1a and 1b; Supporting Information Fig. S1 ). In addition, IHC analysis of 20 pairs of human prostatic tumor samples before and after ADT revealed that expression of Notch3 was upregulated in PCa specimens 3 months post ADT than that from the same patients before ADT (Figs. 1c and 1d) .
Consistent with the observation in clinical samples, we also observed a significantly higher expression of Notch 3 receptor in androgen independent PCa cell line C4-2 compared to its paired androgen dependant PCa cell line, LNCaP, at both mRNA and protein levels (Fig. 1e ). Considering that previous study suggested that cancer stem cell (CSC) might Molecular Cancer Biology be the origin for development of castration-resistant PCa, 18, 19 and that the PSA 2/lo subpopulation of LNCaP cells possesses CSC properties, 20 we performed experiments to separate PSA 2/lo subpopulation from LNCaP cells and examined expression levels of Notch receptors in PSA 2/lo and PSA 1 subpopulation, respectively. As shown in Figure 1f , compared to PSA 1 cells, the PSA 2/lo cells exhibited higher expression levels of Notch3 and Notch4. Taken together, these data indicate an elevated expression of Notch receptors, especially Notch 3, in CRPC and suggest that Notch signaling may play a role in the development of CRPC.
Notch signaling is activated in LNCaP cells under the treatment of androgen deprivation
Given that upregulated expression of Notch receptors is correlated with progression of CRPC, we next investigated whether Notch signaling is directly activated by ADT or not. To observe the dynamics of the Notch signaling, we herein constructed a lentiviral fluorescent reporter system of the Notch signaling (pLVX-CSLP-AcGFP), in which expression of AcGFP is driven by a promoter containing multiple CSLbinding sites (Fig. 2a) . To test the reliability of the Notch reporter system, we first established HEK293T-NR cells by infection of this Notch reporter (NR) lentivirus into HEK293T cells. Then, we transiently transfected HEK293T-NR cells with a NICD1 overexpressing plasmid or the control vector plasmid to observe the response of the system to activation of the Notch signaling. As expected, a significantly enhanced fluorescent signal of AcGFP was detected in NICD1 overexpressed cells compared to control cells (Supporting Information Fig. S2 ). After the validity of the reporter system, we infected LNCaP cells with the lentivirus to establish LNCaP-NR cells using the same strategy. The LNCaP-NR cells were treated with a Notch ligand, JAG1-Fc (20 lg/ml) protein, to activate Notch signaling or vehicle and we observed a higher intensity of AcGFP fluorescent signal in JAG1-Fc treated cells (Fig. 2b) , which indicated that the Notch reporter system can faithfully report Notch activation in established cell lines in vitro.
To evaluate the response of the Notch signaling to androgen deprivation in androgen-dependent PCa cells, LNCaP-NR cells were cultured under androgen-deprived conditions, i.e., using RPMI supplemented with 10% charcoal dextran stripped serum (CDSS) or RPMI-10%FBS plus 10 lM enzalutamide (an androgen receptor antagonist). By flow cytometry analysis, a strikingly improved intensity of AcGFP fluorescent signal was observed in the cultures containing 10% CDSS for 7 days, while the AcGFP intensity dropped back to the basic level after changing the conditional medium back to the normal medium with androgen for 2 weeks (Fig. 2c) . In addition, we observed an upregulated expression of Notch3 at both mRNA and protein levels, as revealed by qRT-PCR, western blotting and IF staining analyses, under the culture condition with 10% CDSS (Figs. 2d-2f) . In sharp contrast, no significant changes of Notch1, Notch2 and Notch4 expression were observed under this culture condition. Consistently, we isolated the nuclear proteins and observed an increase in the nuclear translocation of NICD3 under the same condition (Fig. 2f) . Similarly, addition of 10 lM enzalutamide, an antagonist of androgen receptor (AR), into the culture medium showed similar effects, that is, enhancement of AcGFP fluorescent signal, upregulation of Notch3 expression and increase in NICD3 nuclear translocation (Figs. 2g-2i ). In addition, after treatment of 10 lM enzalutamide, Notch3 expression was also upregulated in another androgen dependent PCa cell line LAPC4 cells (Supporting Information Fig.  S3 ). Collectively, these results indicate that Notch signaling is activated by androgen deprivation and that among the four Notch receptors, Notch3 appears to be a selective endogenous Notch receptor that was activated by androgen deprivation in LNCaP cells in vitro.
Activation of the Notch signaling promotes the resistance to androgen deprivation in LNCaP cells
Although the above data suggest that under physiological conditions, androgen deprivation can activate the Notch signaling though activation of Notch3 in LNCaP cells, to determine whether activation of Notch3 contributes to the resistance to androgen deprivation in LNCaP cells and whether activation of the Notch signaling though other Notch receptors (Notch1, Notch2 and Notch4) have also similar effects, we developed a doxycycline (Dox) inducible exogenous NICD expression lentiviral vector system for overexpression of four various NICD (1-4) respectively to achieve an inducible activation of the Notch signaling (Supporting Information Fig. S4 ). Lentiviruses were infected into LNCaP cells to establish related subclone cell lines and were named LNCaP-NICD1, LNCaP-NICD2, LNCaP-NICD3 and LNCaP-NICD4, respectively. As shown in Figure 3a , expression of Notch target genes (Hey1 and Hes1) were significantly increased by both qRT-PCR and western blot assays, indicating that Dox-induced overexpression of any of the four NICDs could activate the Notch signaling. In addition, Dox did not influence cell growth in LNCaP cells (Supporting Information Fig. S5 ). Previous studies reported that the response of tumor cells under ex vivo 3D culture conditions to drug treatment more reliably reflects the cell response in vivo, 21-24 so we applied the same culture conditions to explore the effect of activation of the Notch signaling on resistance to ADT. Activation of the Notch signaling was achieved by inclusion of Dox for 2 days before LNCaP-NICD1-4 cells were collected for the 3D culture and then maintained the presence of Dox during the process of the 3D culture. The cells were cultured in the medium containing 10% CDSS combined with or without 10 lM enzalutamide. The number of survival colonies was counted every 2 days for 6 days to evaluate the resistance to androgen deprivation after Notch signaling activation. We found that the number of survival colonies was significantly increased in Notch activated LNCaP cells by any of the four NICDs (Fig. 3b) . These
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Activation of the Notch signaling upregulates p38MAPK signaling and expression of Bcl-2 in LNCaP cells
Notch pathway has been demonstrated to crosstalk with p38MAPK signaling in retina cells 25, 26 and to regulate expression of Bcl-2 family proteins in many types of cancer. 27, 28 P38MAPK signaling and Bcl-2 protein family have been widely shown to contribute to the androgen independence acquisition of PCa. [29] [30] [31] [32] [33] [34] Therefore, we next investigated whether activation of the Notch signaling enhances ADT resistance though regulation of the p38MAPK signaling and expression of Bcl-2 family proteins in ADPC cells. We used western blotting analysis to examine protein expression of active form of p38 (phospho-p38, p-p38), Bcl-2 and Bax in LNCaP-NICD1-4 cells treated with Dox to activate the Notch signaling or DMSO as a control. As shown in Figure  3c , activation of the Notch signaling by any of the NICDs upregulated protein levels of p-p38 and Bcl-2 but did not alter expression of Bax in LNCaP cells. We next determined whether the ADT resistance induced by activation of the Notch signaling is depended upon activation of the p38MAPK signaling and upregulation of Bcl-2. Under androgen-deprived culture conditions, using RPMI supplemented with 10% CDSS and 10 lM enzalutamide, LNCaP-NICD1-4 cells in 3D matrigel cultures were treated with Dox to activate Notch signaling and split into four groups, i.e., in the presence of SB203580 (a specific chemical inhibitor of p38MAPK signaling), ABT-199 (a specific chemical inhibitor of Bcl-2), a combination of SB203580 and ABT-199 or the vehicle, respectively. Three days after the treatment, survived colonies were counted. As shown in Figure 3d , the number of survived colonies was markedly decreased in cultures treated with SB203580 or ABT-199 compared to the control cultures. Notably, the number of survived colonies was more significantly decreased in the cultures treated with a combination of SB203580 and ABT-199 than that treated with either of them. Taken together, our results suggest that activation of the Notch signaling promotes the resistance to androgen deprivation in LNCaP cells, possibly through the upregulation of the p38MAPK signaling and Bcl-2.
Inhibition of the Notch signaling results in an enhanced sensitivity to androgen deprivation in androgen-sensitive PCa cells Given our finding that Notch signaling is activated by androgen deprivation and promotes the resistance to androgen deprivation in LNCaP cells, we put forward a hypothesis that inhibition of the Notch signaling may enhance the sensitivity to androgen deprivation in androgen-sensitive PCa cells. To test this possibility, we selected three androgen-sensitive cell lines, LNCaP cells (androgen dependent and sensitive), C4-2 and 22Rv1 cells (androgen independent but sensitive), which all respond to androgen deprivation. 35, 36 RPMI medium supplemented with 10% CDSS and 10 lM enzalutamide was used as androgen deprivation medium for culturing C4-2 and 22Rv1 cells. Considering that 3D-grown LNCaP cells do not survive in RPMI-10% CDSS (Fig. 3b) , we decided to use RPMI-10% FBS plus 10 lM enzalutamide as androgen deprivation medium for culturing LNCaP cells. In addition, we employed DAPT, a g-secretase inhibitor (GSI) that inhibits the Notch signaling as an adjuvant treatment to androgen deprivation in the cultures of LNCaP, C4-2 and 22Rv1 cells. We first tested the impact of Notch inhibition on proliferation of these PCa cell lines by CCK-8 assay. The result revealed that a combination of Notch inhibition using DAPT (30 lM) with androgen deprivation led to a lower proliferation in all these three cell lines than DAPT or enzalutamide treatment alone or the control (Fig. 4a) . Furthermore, we performed a 3D colony formation assay and found that not only the percentage of large (diameter >100 lm) and middle colonies (diameter 50-100 lm) but also the numbers of total colonies were markedly decreased in all of the three cell lines under the androgen-deprived conditions in the presence of the Notch signaling inhibitor (Fig. 4b) . To further determine effects of combined therapy on PCa cell survival, we performed an apoptosis assay 2 days after androgen deprivation in the presence or absence of the Notch signaling inhibitor. We found that after inhibition of the Notch signaling, the proportion of apoptotic cells was significantly increased in all of the cell lines, indicating a more effective response to androgen deprivation (Fig. 4c) . Moreover, western blot analysis revealed that Notch inhibition downregulated p-p38 and Bcl-2 (but upregulated Bax in 22Rv1 cells) in a DAPT dosedependent manner in PCa cells. In addition, we also carried out specific Notch3 knockdown using siRNA to inhibit the Notch signaling in both LNCaP and LAPC4 cells. Consistent with our previous findings, knockdown of Notch3 significantly decreased expression of p-p38 and Bcl-2 in both LNCaP and LAPC4 cells (Supporting Information Fig. S6 ). Taken together, these data indicated again that inhibition of the Notch signaling can enhance the sensitivity to androgen deprivation in androgen sensitive cells (Fig. 4d) .
Inhibition of the Notch signaling enhances the efficacy of ADT on tumor growth in vivo
To further determine the impact of Notch signaling inhibition on the response to ADT in vivo, we established a subcutaneous xenograft model by inoculation of androgen responsive 22Rv1 cells into male athymic nude mice. After inoculation, mice were treated by castration along with enzalutamide (10 mg/kg, n 5 10) or a sham surgery (n 5 10). Subsequently, mice in both of ADT treatment group and control group were treated with DAPT (60 mg/kg) or vehicle to simultaneously inhibit the Notch signaling or not. Enzalutamide, DAPT or vehicle was injected subcutaneously daily for 15 days (Fig. 5a ). Remarkably, a combination of ADT with a Notch signaling inhibitor exhibited a maximal inhibition of tumor growth with a minimal tumor volume and lightest tumor weight 15 days after inoculation, compared to treatment with ADT or inhibition of the Notch signaling alone (Fig. 5b) . Consistently, immunohistochemical (IHC) staining assay revealed a dramatic repression of Ki67 in tumor tissues of mice treated with ADT plus DAPT (Fig.  5c ). In addition, expression of CD31, a marker of vascular endothelial cell, was also found to be downregulated after inhibition of the Notch signaling in combination with ADT, which indicated that Notch signaling inhibition might lead to a decreased angiogenesis of microvessel in xenograft (Fig. 5c) . Taken together, these results suggest that inhibiting the Notch signaling as an adjuvant therapy can enhance the antitumor effect of ADT in vivo.
Discussion
Although ADT has been a well-established treatment strategy for metastatic PCa, it remains a major challenge to elucidate the mechanism of resistance to ADT and to enhance its efficacy. In our study, we uncover an essential role of Notch signaling in response to ADT. First, we demonstrate a close association between upregulated Notch receptors and development of CRPC. Second, we find androgen deprivation activates the Notch signaling, and activation of the Notch signaling enhances the resistance to ADT in androgen dependent PCa cells such as LNCaP cells. Third, inhibition of the Notch signaling using a g-secretase inhibitor, DAPT, significantly enhances the efficacy of ADT in androgen sensitive PCa cells in vitro and in vivo. Therefore, our study suggests Notch signaling contributes to the resistance to ADT and block of Notch signaling may become a promising adjuvant therapy to ADT.
Specific Notch pathway components such as Jagged 1, Notch1 and Notch3 have been demonstrated to be upregulated in advanced PCa and activation of the Notch signaling contributes to tumor metastasis and chemotherapy resistance in PCa. 13, [37] [38] [39] [40] However, the role of Notch signaling in response to androgen deprivation in PCa remained unclear.
In our study, we found that under androgen-deprived condition, Notch signaling is activated via activation of Notch3. By inhibiting Notch signaling activation after androgen deprivation, the resistance to androgen deprivation is significantly decreased in PCa cells, as evidenced by inhibition of growth, a decreased colony formation capacity and an increased apoptosis. Conversely, activation of the Notch signaling enhances the resistance to androgen deprivation in PCa cells. Moreover, not only Notch signaling is endogenously activated through activation of Notch3 under androgen-deprived conditions, but also exogenous activation of the Notch signaling through other Notch receptors (Notch1, Notch2 and Notch4) exhibits similar effects on androgen deprivation resistance in LNCaP cells. Consistent with our findings, a recent study by Stoyanova et al. shows that mouse prostate tumors driven by NICD1 in combination with activation of multiple oncogenic pathways (such as AKT, Myc and Ras) exhibit a castrationresistant phenotype. 41 Thus, all the experiments support the notion that activation of the Notch signaling induced by ADT enhances the resistance to ADT in PCa.
Mechanistically, it is well known that Notch signaling interacts with many other different downstream cascades to regulate critical cellular processes. 42 In our study, we found that p38MAPK signaling and anti-apoptotic Bcl-2 family proteins were regulated by Notch signaling in PCa cells. Notch activation through NICD1-4 all significantly upregulates expression of p-p38 and Bcl-2. On the contrary, inhibition of the Notch signaling leads to a downregulation of p-p38 and Bcl2 in androgen sensitive PCa cells. Furthermore, pharmacological inhibition of Bcl-2 and the p38MAPK signaling abrogates the ADT-resistant effects induced by activation of the Notch signaling. Thus, these results suggest Notch signaling is capable of influencing the resistance to ADT possibly through the regulation of the p38MAPK signaling and Bcl-2 family members. However, the mechanism for upregulation of the Notch signaling after ADT and the potential upstream signaling pathway remains unclear. In a recent report by Milanovic et al. Wnt signaling is implicated to be upstream to induce upregulation of the Notch signaling to acquire stemness features in therapy-induced senescence (TIS) lymphomas. 43 In addition, Wnt/b-catenin signaling pathway has been identified as an ADT-regulated pathway in advanced PCa. 44 Considering these findings together, we speculated that activation of the Wnt/b-catenin signaling pathway, such as overexpression of b-catenin, might be an underlying mechanism for upregulation of the Notch signaling in PCa cells after ADT. Detailed mechanism still needs to be further investigated.
According to latest clinical studies, ADT, as a standard of care for metastatic PCa, is suggested to be modified to combine with docetaxel chemotherapy. 11, 12 It has been shown that activation of the Notch signaling enhances docetaxel chemoresistance in PCa and inhibition of the Notch signaling using GSI can significantly enhance the antitumor effects of docetaxel in PCa in vivo and in vitro. 13, 14 Considering these findings together with our current research, activation of the Notch signal pathway seems to obstruct the efficacy of both ADT and chemotherapy. As a result, inhibition of the Notch signaling not only enhances the efficacy of chemotherapy but also that of ADT. Thus, inhibition of the Notch signaling might be a promising adjuvant therapy for ADT-chemo therapy.
In summary, we demonstrate that Notch signaling activation contributes to the resistance to ADT in PCa. Inhibition of the Notch signaling using DAPT significantly enhances the anti-tumor efficacy of ADT. Thus, targeting Notch signaling may serve as a promising adjuvant to ADT or ADT-chemo therapy.
